Oral semaglutide (Rybelsus) represents the pharmaceutical benchmark for oral GLP-1 receptor agonism. Preclinical research compounds in this class — native GLP-1, Retatrutide, Orforglipron — each offer different research utility profiles. Understanding the mechanistic distinctions between these compounds is foundational to designing experiments that interrogate the incretin axis with adequate pharmacological precision.
The incretin system comprises two principal gut-derived hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both are released postprandially from enteroendocrine cells — L-cells and K-cells respectively — and exert coordinated effects on pancreatic beta-cell insulin secretion in a glucose-dependent manner. This glucose-dependency is pharmacologically significant: incretin-based agents potentiate insulin release only when circulating glucose is elevated, substantially reducing the hypoglycemia risk associated with other secretagogue classes.
GLP-1 receptor (GLP-1R) signaling proceeds primarily through Gs-coupled cAMP elevation, activating protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (Epac2). This cascade potentiates glucose-stimulated insulin secretion, suppresses glucagon secretion from alpha cells, slows gastric emptying, and engages central satiety circuits via hypothalamic and brainstem GLP-1R populations. The peripheral and central actions together produce the metabolic phenotype observed in GLP-1R agonist research: reduced food intake, decelerated gastric transit, and improved glycemic parameters.
Native GLP-1 (7-37 amide or 7-36 amide) has a plasma half-life of approximately 1–2 minutes in vivo, attributable to rapid degradation by dipeptidyl peptidase-4 (DPP-4) at the N-terminal Ala-Glu dipeptide and renal clearance. This short half-life, while limiting therapeutic utility, makes native GLP-1 an ideal positive control or acute stimulation tool in preclinical models where pulse pharmacology is deliberately required. For researchers new to peptide pharmacology, this distinction between native hormone kinetics and engineered analog stability is a critical design consideration.
The development of pharmaceutical GLP-1 analogs — beginning with exenatide and culminating in the semaglutide class — sought to extend half-life through structural modifications: amino acid substitution at position 8 (Aib or alpha-methylalanine to resist DPP-4), fatty acid conjugation for albumin binding, and incorporation of Cα-methylated residues. Semaglutide’s C18 fatty diacid moiety linked via a hydrophilic spacer to Lys26 achieves albumin binding with a dissociation constant in the low micromolar range, extending half-life to approximately 165 hours in humans.
The development of an oral semaglutide formulation (Rybelsus, approved 2019) required addressing a fundamental barrier: peptide permeation across the gastrointestinal epithelium. The sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) absorption enhancer technology achieves localized permeabilization of the gastric mucosa, enabling transcellular uptake of intact semaglutide molecules. Oral bioavailability in human studies averages approximately 0.4–1%, with a narrow absorption window in the stomach. SNAC creates a transient local pH microenvironment near the gastric mucosa that reduces semaglutide aggregation and increases membrane permeability, without causing systemic absorption enhancement. This mechanism — confined, transient, and epithelium-local — represents one of several strategies explored for overcoming oral peptide delivery challenges.
The following table summarizes key pharmacological and translational characteristics of the principal GLP-1 class compounds used in preclinical metabolic research. Researchers selecting compounds for specific experimental designs should cross-reference receptor selectivity profiles against the signaling endpoints under investigation.
| Compound | Receptor Targets | Structure Type | Oral BA (%) | Half-Life (Human) | Status | Key Mechanism Distinction |
|---|---|---|---|---|---|---|
| Native GLP-1 (7-36 amide) | GLP-1R (selective) | 30-aa peptide, endogenous | Not applicable (parenteral/perfusion) | 1–2 min | Research tool / endogenous hormone | Ultra-short pulse agonism; DPP-4 sensitive; ideal for acute secretion assays |
| Semaglutide (oral) | GLP-1R (selective) | Peptide analog; C18 fatty diacid, Aib8 | ~0.4–1% (SNAC-enabled) | ~165 h | FDA-approved (Rybelsus, Ozempic); pharmaceutical benchmark | SNAC gastric absorption; albumin-mediated protraction; DPP-4 resistant |
| Tirzepatide | GLP-1R + GIP-R (dual) | Peptide analog; C20 fatty diacid, GIP-based backbone | Not orally bioavailable (injectable only) | ~118–160 h | FDA-approved (Mounjaro, Zepbound); injectable | GIP-R co-agonism potentiates GLP-1R response; superior weight effect in trials |
| Retatrutide | GLP-1R + GIP-R + GCGR (triple) | Peptide analog; C20 fatty diacid, modified GIP scaffold | Not orally bioavailable (injectable only); research use oral capsule formulations in preclinical settings | ~6 days (estimated) | Phase 2/3 clinical investigation; research compound | GCGR agonism adds hepatic glucose output regulation and thermogenic contribution |
| Orforglipron | GLP-1R (selective) | Non-peptide small molecule (oral) | ~65–75% (no formulation enhancer required) | ~12–15 h | Phase 3 clinical investigation; research compound | Small-molecule allosteric/orthosteric GLP-1R agonist; no SNAC required; once-daily oral |
BA = bioavailability. Values represent published preclinical and early clinical data; human pharmacokinetics may differ from rodent models. All compounds listed for laboratory research context. Certificates of Analysis available.
The following data synthesizes published preclinical findings from diet-induced obesity (DIO) mouse and rat models. Values are approximate ranges derived from peer-reviewed literature; inter-study variability is substantial depending on dose, route, duration, and animal background. This table is provided to illustrate relative effect magnitudes for research design guidance, not as head-to-head comparison data from a single controlled study.
| Compound | Body Weight Change (% from baseline, DIO rodent) | Glucose AUC Reduction (OGTT, % vs vehicle) | Insulin Secretion Effect | Gastric Emptying Rate | Preclinical Model Reference |
|---|---|---|---|---|---|
| Native GLP-1 (infusion) | Minimal (acute dosing); −5 to −10% (chronic infusion, high dose) | 20–35% (acute administration) | Robust potentiation; rapid onset, rapid offset | Significant slowing (dose-dependent) | Knudsen et al. 2010; Drucker 2018 |
| Semaglutide (injectable equivalent, preclinical) | −15 to −25% (chronic, 4–8 wk) | 40–60% | Sustained potentiation; glucose-dependent | Moderate-to-strong slowing | Lau et al. 2015; Blundell et al. 2017 |
| Tirzepatide (preclinical) | −20 to −35% (chronic, comparable dose) | 50–65% | Enhanced vs semaglutide; GIP-R synergy | Moderate slowing | Coskun et al. 2022; Min et al. 2021 |
| Retatrutide (preclinical) | −25 to −45% (highest reported; GCGR contribution) | 55–70% | Strong; GIP-R + GLP-1R additive; GCGR modulates fasting glucose | Moderate slowing (GCGR partially offsets GLP-1R effect) | Urva et al. 2024; Finan et al. 2015 (triple agonist class) |
| Orforglipron (preclinical) | −15 to −22% (DIO mouse, 4 wk) | 40–55% | Comparable to semaglutide class at matched GLP-1R engagement | Moderate slowing | Horiuchi et al. 2023; Griffith et al. 2022 |
All values approximate; derived from published literature in preclinical models. Effect magnitude is dose- and regimen-dependent. Rodent data does not predict human outcomes. For detailed bioavailability comparisons across oral and injectable routes, see the linked overview.
| Research Endpoint | Preferred Compound | Rationale | Considerations |
|---|---|---|---|
| Acute GLP-1R signaling / cAMP kinetics | Native GLP-1 (7-36 amide) | Ultra-short half-life enables precise pulse-response characterization; DPP-4 sensitivity can be modulated with sitagliptin pre-treatment | Requires IV or direct perfusion; limited to short observation windows |
| Chronic GLP-1R satiety circuitry mapping | Semaglutide analog or Orforglipron | Sustained receptor occupancy enables chronic central pathway activation; hypothalamic arc/NTS studies | Long half-life complicates washout design; receptor internalization may occur |
| Oral bioavailability and GI peptide absorption research | Orforglipron | High intrinsic oral BA (~70%) without formulation enhancers; ideal for studying GLP-1R oral pharmacodynamics independently of SNAC effects | Small-molecule; different absorption mechanism from peptide analogs |
| Triple receptor agonism / comparative receptor pathway dissection | Retatrutide | Simultaneous GLP-1R + GIP-R + GCGR engagement; useful for studying receptor interaction and additive/synergistic metabolic effects | Cannot isolate individual receptor contributions without selective antagonists |
| GLP-1 class body composition endpoints (adipose, lean mass) | Retatrutide or Tirzepatide analog | GCGR/GIP-R co-agonism produces superior fat mass reduction in DIO models; suitable for studying adipose tissue biology | Multi-receptor mechanism complicates attribution of effects to GLP-1R alone |
| Hepatic glucose output / glucagon axis | Retatrutide | GCGR agonism directly modulates hepatic glucose production; enables investigation of glucagon counter-regulatory pathways alongside incretin activity | GCGR agonism can be metabolically paradoxical; careful dosing and endpoints required |
| Beta-cell preservation / islet biology | Native GLP-1 or semaglutide analog | Clean GLP-1R selectivity avoids confounding from GIP-R or GCGR on islet morphology; well-characterized in streptozotocin and Zucker rat models | GIP-R also expressed on beta cells; dual agonists may be informative depending on hypothesis |
| SNAC formulation / oral absorption mechanism research | Semaglutide + SNAC system (pharmaceutical reference) | SNAC mechanism itself is an active research topic; semaglutide serves as the index molecule for absorption enhancer studies | SNAC confounds pure pharmacodynamic GLP-1R studies; use Orforglipron as SNAC-free control |
GLP-1R is a class B GPCR with a large extracellular domain (ECD) involved in peptide ligand recognition. The canonical two-domain binding model describes initial contact of the peptide C-terminus with the ECD, followed by N-terminal insertion into the transmembrane bundle to activate the receptor. Native GLP-1 and semaglutide share this binding mode despite substantial structural differences introduced by the fatty acid modification and Aib8 substitution. Receptor internalization following activation proceeds via beta-arrestin recruitment and endosomal trafficking; evidence from preclinical endosome signaling studies suggests that GLP-1R continues to signal from endosomal compartments post-internalization, a phenomenon with implications for agonist bias research.
Biased agonism at GLP-1R — differential activation of Gs vs beta-arrestin pathways — is an active preclinical research area. Some research ligands preferentially activate cAMP production with reduced receptor internalization (Gs-biased), potentially offering sustained signaling without desensitization. Native GLP-1 is a relatively balanced agonist. Whether semaglutide’s modifications confer any bias is debated in the literature. Orforglipron’s small-molecule mechanism may offer a distinct bias profile, though published bias data remain limited as of 2025.
GIP receptor (GIP-R), like GLP-1R, is a class B GPCR expressed on pancreatic beta cells, adipocytes, osteoblasts, and central neurons. GIP-R signaling was initially regarded as redundant with GLP-1R at the beta cell but is now recognized to contribute distinct effects on adipose tissue lipid storage and bone metabolism. The pharmacological rationale for dual GLP-1R/GIP-R agonism (tirzepatide) rests on observed synergy: GIP-R agonism at the beta cell potentiates cAMP responses to GLP-1R activation through receptor heterodimer interactions or pathway convergence, producing insulin secretion magnitudes exceeding either agonist alone. In adipose tissue, GIP-R agonism facilitates lipid uptake under hyperinsulinemic conditions — paradoxically — yet this effect appears to promote metabolic substrate clearance in preclinical models rather than pathological fat accumulation.
Retatrutide extends dual agonism to include the glucagon receptor (GCGR), creating what investigators term a triagonist or triple incretin receptor agonist. GCGR activation in isolation increases hepatic glucose output, raises circulating free fatty acids, and increases energy expenditure through thermogenic mechanisms. In the context of simultaneous GLP-1R agonism — which suppresses glucagon and reduces hepatic glucose output — the net GCGR effect is substantially modified. The result in preclinical DIO models is enhanced fat oxidation and thermogenesis without the hyperglycemic liability of pure GCGR agonism. This Retatrutide mechanism overview explores the triagonist pharmacology in greater depth.
The additive weight reduction observed with Retatrutide in Phase 2 data (up to approximately 24% body weight loss at 48 weeks, human trial) substantially exceeds tirzepatide-class outcomes and far exceeds pure GLP-1R agonism. Preclinical rodent data predicted this rank order of efficacy, though absolute magnitudes differ between species. For laboratory researchers studying tissue repair, inflammation, and metabolic pathways involving multiple signaling axes, the triagonist profile offers a pharmacological probe unavailable in approved therapeutics.
Orforglipron (LY3502970, Eli Lilly) belongs to a class of orally bioavailable non-peptide GLP-1R agonists that engage the receptor through the transmembrane bundle rather than the ECD. This allosteric/orthosteric pocket binding eliminates the formulation challenges intrinsic to peptide oral delivery: no SNAC, no special fasting requirement, no window-of-absorption pharmacokinetics. Oral bioavailability is approximately 65–75% in preclinical species, far exceeding any peptide GLP-1 analog with or without absorption enhancers.
The small-molecule binding mode confers a distinct receptor conformation. Published cryo-EM and molecular dynamics data (Griffith et al. 2022; Horiuchi et al. 2023) demonstrate that non-peptide agonists stabilize a partially active receptor conformation with Gs coupling efficiency comparable to peptide agonists but potentially distinct beta-arrestin recruitment profiles. This mechanistic difference makes Orforglipron particularly valuable for studies designed to dissect GLP-1R conformational pharmacology or to use a GLP-1R agonist in oral models where formulation confounds must be eliminated. Our Orforglipron batch BH-250523 was independently tested at 99.68% purity with a full Certificate of Analysis available.
For researchers interested in comparing oral versus injectable delivery routes for GLP-1 class compounds, Orforglipron serves as the clearest oral bioavailability reference point, uncomplicated by the low and variable absorption inherent to SNAC-based peptide formulations.
A critical distinction in any comparative discussion of this compound class is the regulatory and use-context boundary between approved pharmaceuticals and research compounds. Oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and related approved agents are medicines manufactured under cGMP conditions, subject to pharmacovigilance, and dispensed through licensed medical channels for diagnosed conditions. Research compounds — including native GLP-1 peptides, Retatrutide, Orforglipron, and other preclinical tools — are supplied exclusively for in vitro and in vivo laboratory investigation under institutional oversight. The pharmacological literature cited in this article encompasses both clinical and preclinical data; where clinical data from approved drugs is referenced, it serves as a mechanistic comparator to preclinical observations, not as a claim of equivalence between research compound formulations and pharmaceutical products.
All compounds available through our research catalog are supplied strictly for laboratory research use only (RUO), with documentation including independent third-party Certificates of Analysis. Our GLP-1 batch BH-250516 returned a purity of 99.77% on independent HPLC analysis. Researchers are responsible for compliance with all applicable institutional, local, and national regulations governing research compound use.
Rodent DIO models — the primary preclinical framework for metabolic compound evaluation — have well-documented limitations in predicting human pharmacodynamic outcomes. High-fat diet-induced obesity in C57BL/6J mice produces a metabolic syndrome-like phenotype, but the degree of hyperglycemia, adiposity distribution, and incretin sensitivity differs substantially from human type 2 diabetes or obesity. Effect magnitudes in rodent models (particularly body weight reduction) reliably overestimate human outcomes for GLP-1 class compounds, likely due to differences in body composition ratios, metabolic rate scaling, and central GLP-1R circuit organization between species.
For oral GLP-1 analog delivery research specifically, rodent stomach physiology (single compartment, squamous forestomach, continuous gastric acid secretion) creates SNAC pharmacokinetics that differ from the human fasting stomach context for which oral semaglutide was optimized. Researchers using SNAC-based oral peptide formulations in rodents should account for these anatomical differences in experimental design and data interpretation.
Non-human primate (NHP) models provide more translationally relevant data for GLP-1 pharmacokinetics and oral bioavailability, but logistical and ethical constraints limit their routine use. Where NHP data is cited in the literature for compounds in this class, it typically supports reduced effect magnitudes relative to rodent findings and closer approximation to human outcomes.
Reproducibility and compound integrity are foundational to valid preclinical research. Synthesis impurities, incorrect enantiomers, or subthreshold purity can produce artifactual pharmacological effects or fail to reproduce published data. Researchers should require independent third-party analytical certification — not manufacturer self-certification alone — for any peptide or small-molecule research compound. Identity confirmation via mass spectrometry (ESI-MS or MALDI-TOF) and purity quantification by HPLC are minimum standards. Endotoxin testing is additionally important for in vivo administration.
We provide independently verified Certificates of Analysis for all compounds, including our GLP-1 (batch BH-250516, 99.77% purity) and Orforglipron (batch BH-250523, 99.68% purity), with third-party HPLC and MS documentation. Institutional animal use committees (IACUCs) and ethics review boards increasingly require compound purity documentation as part of protocol approval; sourcing from vendors with transparent independent CoA practices streamlines this requirement.
The GLP-1 receptor agonist compound class encompasses a pharmacological spectrum from the endogenous 30-amino-acid hormone with a two-minute half-life to engineered multi-receptor triagonists with week-long protraction, and from peptides requiring specialized absorption technology to small molecules with intrinsic oral bioavailability approaching 70%. Each compound occupies a distinct research utility niche: native GLP-1 for acute receptor physiology, semaglutide analogs as the clinical benchmark comparator, Retatrutide for dissecting triple incretin receptor axis contributions, and Orforglipron for oral GLP-1R pharmacology without formulation interference.
For researchers building GLP-1-axis study protocols, compound selection should be driven by the specific mechanistic question rather than by clinical familiarity. The availability of well-characterized, high-purity research tools for each node of this receptor system enables precise experimental dissection that would not be possible with approved pharmaceutical agents alone. Access our GLP-1 research compound, Retatrutide, and Orforglipron product pages for current availability and batch-specific documentation.
All GLP-1 class research compounds available through this site are independently tested by third-party analytical laboratories. Batch-specific documentation is publicly accessible:
All compounds are supplied for laboratory research use only. Independent ESI-MS identity confirmation and endotoxin data available on request for in vivo model applications. Visit the full research catalog for current stock and batch documentation.
GLP-1 receptor agonist research compounds differ significantly in receptor binding affinity, downstream cAMP signalling efficiency, and agonist bias profiles. GLP-1 itself shows balanced agonism, while tirzepatide and retatrutide exhibit dual or triple incretin receptor activity (GIP/GLP-1, GIP/GLP-1/glucagon) that creates distinct metabolic research endpoints. GLP-1 receptor selectivity comparisons between study compounds are therefore not a simple potency hierarchy but a reflection of mechanistically distinct pharmacological profiles with different applications in metabolic research.
GLP-1 research compound stability varies considerably across the compound class, with native GLP-1(7-36) amide having a plasma half-life of approximately 2 minutes due to DPP-4 cleavage, while long-acting analogues like semaglutide achieve half-lives exceeding 160 hours via albumin binding and DPP-4-resistant modification. GLP-1 research protocol design must therefore specify which compound analogue is being studied, at what dose interval, and via which administration route to ensure data comparability and meaningful endpoint selection.
GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone secreted natively by intestinal L-cells in response to nutrient ingestion. It activates the GLP-1 receptor to potentiate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and signal satiety. Its plasma half-life is approximately 1–2 minutes due to rapid DPP-4 degradation and renal clearance, limiting its utility beyond acute experimental applications. Semaglutide is an engineered analog of GLP-1 designed for extended half-life: an Aib8 substitution confers DPP-4 resistance, and a C18 fatty diacid chain linked via a hydrophilic spacer enables tight albumin binding that dramatically slows renal clearance, producing a half-life of approximately 165 hours. In preclinical research contexts, native GLP-1 is preferred for acute pulse-response experiments; semaglutide analogs are used as benchmark compounds for chronic GLP-1R engagement studies. See our beginner’s guide to research peptides for foundational context.
Retatrutide (LY3437943) is an investigational peptide agonist that simultaneously activates three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIP-R), and the glucagon receptor (GCGR). This triple receptor engagement profile distinguishes it from semaglutide (GLP-1R selective) and tirzepatide (GLP-1R + GIP-R dual). The GCGR agonism component contributes to enhanced hepatic fat oxidation, increased thermogenic energy expenditure, and — when balanced against GLP-1R-mediated glucagon suppression — improved glycemic control without the hyperglycemia associated with isolated GCGR activation. In DIO rodent models, Retatrutide-class triagonists produce body weight reductions exceeding dual agonists at comparable doses. As of 2025, Retatrutide is in Phase 3 clinical investigation. In preclinical research, it serves as a tool for dissecting triple incretin receptor axis pharmacology. More detail is available on our Retatrutide research compound page and in our Retatrutide mechanism article.
Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike all previous GLP-1R agonists (which are peptide or peptide-analog structures), Orforglipron is a low-molecular-weight organic molecule that binds the GLP-1R transmembrane bundle directly, without requiring the extracellular domain engagement critical to peptide agonists. This structural difference eliminates the oral bioavailability problem inherent to peptide GLP-1 analogs: Orforglipron achieves approximately 65–75% oral bioavailability in preclinical species without SNAC or any special formulation technology. In preclinical models, GLP-1R activation by Orforglipron produces metabolic effects qualitatively similar to semaglutide — reduced food intake, lower body weight, improved glycemic parameters — though the receptor conformation stabilized may differ, with potential implications for agonist bias. Orforglipron is currently in Phase 3 clinical trials. As a research compound, it is uniquely suited for oral GLP-1R pharmacology studies where formulation variables must be minimized. Our Orforglipron research compound is independently tested to 99.68% purity (batch BH-250523).
GLP-1 class compounds are used across a range of preclinical research applications. In vitro, they are applied to isolated pancreatic islet preparations, beta-cell lines (MIN6, INS-1), hypothalamic neuron cultures, and GLP-1R-overexpressing cell systems to interrogate receptor signaling, internalization, biased agonism, and downstream pathway activation (cAMP, PKA, Epac2, ERK1/2). In vivo, they are administered to DIO mouse or rat models to evaluate effects on body weight, glycemic parameters (OGTT, IPGTT), food intake, gastric emptying, and tissue-level outcomes (pancreatic morphology, adipose histology, hepatic lipid). Researchers also use GLP-1R agonists as tools in central nervous system studies, given GLP-1R expression in hypothalamic nuclei, brainstem, and reward circuitry. The choice of specific compound depends on experimental design requirements: half-life, receptor selectivity, and route of administration all influence which compound is most appropriate. See the research utility matrix in this article and our oral GLP-1 analog delivery guide for design considerations. All research use of these compounds must comply with institutional and regulatory requirements.
Triple agonism refers to a single compound simultaneously activating three distinct G-protein-coupled receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIP-R), and the glucagon receptor (GCGR). Each receptor mediates distinct metabolic signaling: GLP-1R activation produces glucose-dependent insulin secretion, suppressed glucagon, slowed gastric emptying, and central satiety signaling; GIP-R activation potentiates beta-cell insulin secretion (synergistically with GLP-1R) and influences adipose tissue lipid metabolism; GCGR activation increases hepatic glucose production and stimulates thermogenic energy expenditure. In isolation, GCGR activation is diabetogenic and catabolic. Within a triple agonist context, GLP-1R-mediated glucagon suppression counterbalances the hyperglycemic potential of GCGR agonism, while GCGR thermogenic effects are preserved, yielding enhanced fat oxidation and greater total energy expenditure than either mono- or dual agonism. Retatrutide is the most advanced triple agonist in clinical development as of 2025. For researchers, the triple agonist pharmacological profile provides a unique tool for investigating receptor cross-talk and additive/synergistic metabolic pathway engagement in preclinical models. Learn more on our Retatrutide compound page.
For the full GLP-1 peptide research overview, see GLP-1 Peptides for Research: Retatrutide and Oral Alternatives. For the oral delivery science behind peptide capsule formats, see Peptides Without Needles.
Biohacker’s research compounds are independently authenticated by accredited third-party laboratories — every batch is tested by specialist analytical chemists before it ships. Our team’s sourcing standards require a minimum 99% HPLC purity floor, ESI-MS mass confirmation, and endotoxin compliance to USP <85> on every lot. Average purity across the catalogue is 99.67%. These are not supplier-claimed figures — they are independently verified results, published batch-by-batch at biohacker.dev-up.click/coas/.
All Biohacker compounds are for laboratory and scientific research use only. They are not intended for human or veterinary use, clinical application, or diagnostic purposes.